Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α-Reference-Cited by-同舟云学术

Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α

Published:1997-04 Issue:1 Volume:36 Page:9-15
ISSN:0162-3109
Container-title:Immunopharmacology
language:en
Short-container-title:Immunopharmacology

Author:

Shannon E.J,Sandoval Felipe,L. Krahenbuhl James

Publisher

Elsevier BV

Subject

Pharmacology

Reference21 articles.

1. Barnhill RL, Doll NJ, Millikan LE, Hastings, RC. Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814–819.

2. Faigle JW, Keberle H, Riess W, Schmie K. The metabolic fate of thalidomide. Experientia 1962; 18: 389.

3. Fernandez LP, Schlegel PG, Baker J, Chen Y, Chao NJ. Does thalidomide affect IL-2 response and production? Exp Hematol 1995; 23: 978–985.

4. Green JN, Benson BC. The spectrophotometric determination of thalidomide in body fluids. J Pharmacol 1961; 13: 117–121.

5. Günzler V, Hanauske-Abel HM, Tschank G, Schulte-Wissermann H. Immunological effects of thalidomide. Arzneim-Forsch/Drug Res 1986; 36(11): 1138–1141.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thalidomide delayed the ability of 4T1 cells to amass into tumors in Balb/c mice;Immunopharmacology and Immunotoxicology;2011-09-27

2. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis;International Immunopharmacology;2010-04

3. Thalidomide Suppressed IL-1β While Enhancing TNF-α and IL-10, When Cells in Whole Blood were Stimulated with Lipopolysaccharide;Immunopharmacology and Immunotoxicology;2008-09

4. Thalidomide and Thalidomide Transformed by pH-Dependent Hydrolysis or by Liver Enzyme Treatment Does Not Impede the Proliferation of Endothelial Cells;Immunopharmacology and Immunotoxicology;2008-01

5. Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide;Current Drug Metabolism;2006-05-01